Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: strokerandomizationimagingto determinehours
  Phrases that lowered it: and safetyefficacy andsafety oftrialthe efficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Blinding: quadruple (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 1 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke NCT02930018 · started 2017 · scored riskier than 84% of active trials completed
• Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy NCT04693715 · started 2021 · scored riskier than 96% of active trials completed
• Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) NCT01422616 · started 2012 · scored riskier than 23% of active trials completed
• Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke NCT02388061 · started 2015 · scored riskier than 98% of active trials completed
• Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2) NCT03340493 · started 2017 · scored riskier than 96% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.